Ad26.COV2.S新冠疫苗的免疫原性研究
该研究为随机双盲安慰剂对照1期临床试验,25名参与者随机接受单剂或两剂Ad26.COV2.S疫苗或安慰剂。结果显示单剂接种后快速诱导结合抗体和中和抗体,以及细胞免疫应答,支持进一步开展3期效力试验。
要点
- 单剂Ad26.COV2.S接种后第8天,90%受试者产生结合抗体,25%产生中和抗体。
- 第57天时,所有单剂接种者均检测到结合抗体和中和抗体。
- 疫苗诱导了多种抗体亚类、Fc受体结合特性及抗病毒功能,并引发CD4+和CD8+ T细胞应答。
核心结论
- 单剂Ad26.COV2.S疫苗可快速诱导结合抗体、中和抗体及细胞免疫应答。
研究设计与样本
- 随机、双盲、安慰剂对照1期临床试验,在美国波士顿单中心开展,共入组25名参与者。
- 参与者随机接受1剂或2剂肌肉注射,剂量为5×10^10或1×10^11病毒颗粒,或安慰剂,于第1天和第57天给药,每组5人。
- 随访至第71天进行中期分析, durability随访将持续2年。
主要发现
- 首次免疫后第8天,90%疫苗受试者检测到结合抗体,25%检测到中和抗体。
- 第57天时,单剂免疫后100%疫苗受试者检测到结合抗体和中和抗体。
- 第71天时,疫苗组 spike 特异性结合抗体几何平均滴度为2432至5729,中和抗体几何平均滴度为242至449。
- 疫苗诱导了多种抗体亚类、Fc受体结合特性及抗病毒功能。
- 疫苗诱导了CD4+和CD8+ T细胞应答。
临床怎么用
- 该1期研究提示单剂Ad26.COV2.S可诱导快速体液和细胞免疫应答,支持开展3期效力试验。
局限性
- 样本量小(25人),为单中心1期研究,中期分析随访至第71天。
- 免疫原性结果不能直接等同于疫苗效力,需3期临床试验确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Control of the global COVID-19 pandemic will require the development and deployment of safe and effective vaccines. OBJECTIVE: To evaluate the immunogenicity of the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in humans, including the kinetics, magnitude, and phenotype of SARS-CoV-2 spike-specific humoral and cellular immune responses. DESIGN, SETTING, AND PARTICIPANTS: Twenty-five participants were enrolled from July 29, 2020, to August 7, 2020, and the follow-up for this day 71 interim analysis was completed on October 3, 2020; follow-up to assess durability will continue for 2 years. This study was conducted at a single clinical site in Boston, Massachusetts, as part of a randomized, double-blind, placebo-controlled phase 1 clinical trial of Ad26.COV2.S. INTERVENTIONS: Participants were randomized to receive 1 or 2 intramuscular injections with 5 × 1010 viral particles or 1 × 1011 viral particles of Ad26.COV2.S vaccine or placebo administered on day 1 and day 57 (5 participants in each group). MAIN OUTCOMES AND MEASURES: Humoral immune responses included binding and neutralizing antibody responses at multiple time points following immunization. Cellular immune responses included immunospot-based and intracellular cytokine staining assays to measure T-cell responses. RESULTS: Twenty-five participants were randomized (median age, 42; age range, 22-52; 52% women, 44% male, 4% undifferentiated), and all completed the trial through the day 71 interim end point. Binding and neutralizing antibodies emerged rapidly by day 8 after initial immunization in 90% and 25% of vaccine recipients, respectively. By day 57, binding and neutralizing antibodies were detected in 100% of vaccine recipients after a single immunization. On day 71, the geometric mean titers of spike-specific binding antibodies were 2432 to 5729 and the geometric mean titers of neutralizing antibodies were 242 to 449 in the vaccinated groups. A variety of antibody subclasses, Fc receptor binding properties, and antiviral functions were induced. CD4+ and CD8+ T-cell responses were induced. CONCLUSION AND RELEVANCE: In this phase 1 study, a single immunization with Ad26.COV2.S induced rapid binding and neutralization antibody responses as well as cellular immune responses. Two phase 3 clinical trials are currently underway to determine the efficacy of the Ad26.COV2.S vaccine. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04436276.
引用
- Stephenson KE, Le Gars M, Sadoff J, et al. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA. 2021. PMID: 33704352. doi:10.1001/jama.2021.3645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。